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Despite improved treatment, a large portion of patients with acute ischemic stroke
due to a large vessel occlusion have poor functional outcome. Further research
exploring novel treatments and better patient selection has therefore been initiated.
The feasibility of new treatments and optimized patient selection are commonly tested
in extensive and expensive randomized clinical trials. in-silico trials, computer-based
simulation of randomized clinical trials, have been proposed to aid clinical trials. In
this white paper, we present our vision and approach to set up in-silico trials focusing
on treatment and selection of patients with an acute ischemic stroke. The INSIST
project (IN-Silico trials for treatment of acute Ischemic STroke, www.insist-h2020.eu)
is a collaboration of multiple experts in computational science, cardiovascular biology,
biophysics, biomedical engineering, epidemiology, radiology, and neurology. INSIST will
generate virtual populations of acute ischemic stroke patients based on anonymized data
from the recent stroke trials and registry, and build on the existing and emerging in-silico
models for acute ischemic stroke, its treatment (thrombolysis and thrombectomy) and the
resulting perfusion changes. These models will be used to design a platform for in-silico
trials that will be validated with existing data and be used to provide a proof of concept of
the potential efficacy of this emerging technology. The platformwill be used for preliminary
evaluation of the potential suitability and safety of medication, new thrombectomy
device configurations and methods to select patient subpopulations for better treatment
outcome. This could allow generating, exploring and refining relavant hypotheses on
potential causal pathways (which may follow from the evidence obtained from clinical
trials) and improving clinical trial design. Importantly, the findings of the in-silico trials will
require validation under the controlled settings of randomized clinical trials.
Keywords: INSIST, in-silico clinical trials, acute ischemic stroke, in-silico modeling, virtual patients, virtual
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INTRODUCTION
Endovascular treatment (EVT) has become the standard of care for patients with acute ischemic
stroke (AIS) after its benefit was demonstrated by multiple randomized clinical trials (RCTs) (1).
Despite improved functional outcome after EVT, up to 66% patients have an unfavorable outcome
and remain functionally dependent (1–3). Functional outcome, generally assessed 90 days after
stroke onset, predominantly depends on the patient’s baseline characteristics including but not
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limiting to age (4), previous comorbidities (5), stroke severity (4,
6), collateral capacity (7, 8), and thrombus characteristics (9, 10).
Delay to receive care strongly reduces the effect of treatment (11–
13). Furthermore, ischemic lesion characteristics like volume and
location, before and after treatment are also known to be strong
predictors of functional outcome after 90 days (14–19).
New AIS trials are focusing on testing new thrombolytics,
improved stent designs and testing the applicability of
thrombectomy to previously understudied patient sub-groups.
However, not more than 10% of the compounds that are tested
in clinical trials get launched in the market (20). By design,
RCTs do not serve the purpose of explaining the ineffectiveness
of treatments. However, this is a task that could be performed
with in-silico approaches (21). Further analysis to explain the
established efficacy of a treatment by in-silico methods may
allow for generation of potential hypotheses. Before these can be
introduced in clinical practice, valiation by RCTs is mandatory.
Computational or in-silico modeling is playing an increasing
role in research and development of biomedical products and
is acknowledged as an alternative to animal studies in some
preclinical trials by regulators (21–23). Statistical models that
accurately describe the most important patient characteristics
can generate “virtual patients.” Combining such virtual patient
populations with in-silicomodels (ISMs) of disease and treatment
will help to set up in-silico trials (ISTs). In such ISTs, virtual
patients receive virtual treatments and effect of treatment on
clinical outcome is estimated (21). This project aims to develop a
platform that enables the execution of ISTs for AIS. The proposed
IST platform aims to be a proof-of-concept to investigate the
extent to which in-silicomodeling can accurately simulate bench-
testing, animal testing, and clinical trial results. After validating
the proof-of-concept, some plausible hypothesesmay emerge due
to the hypotheses-generating nature of this approach. Although
ISTs will not allow for testing these hypotheses, they will be useful
in optimizing trial design, may provide potential explanation into
the causes of (un-) planned effects including less probable clinical
situations (21). We envision that developing such a platform can
considerably contribute towards a depper understanding of the
etiology and pathophysiology of AIS and its treatment effects at
the patient and population levels. In the following sections, we
describe a quantitative approach to develop a platform that can
execute, validate ISTs for AIS, generate and refine hypotheses on
the potential successfulness of new treatments, the suitability of
treatments for specific patient populations and to provide tools
for in-silico evaluation of trial design modeling.
METHODS
To develop and validate a platform to execute an IST, we
intend to implement a 3 fold approach. We want to generate
Abbreviations: INSIST, IN-Silico trials for treatment of acute Ischemic STroke;
MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment
for Acute Ischemic Stroke in the Netherlands; EVT, Endovascular treatment; AIS,
Acute ischemic stroke; RCT, Randomized clinical trials; ISM, in-silico model; IST,
in-silico trial; VVUQ, Verification, Validation, and Uncertainty Quantification;
TAFIa, Thrombin-Activatable Fibrinolysis Inhibitor.
virtual populations of AIS patients and develop ISMs for (1)
thrombosis and thrombolysis, (2) intra-arterial thrombectomy
and (3) microvascular perfusion, cell death, and recovery of brain
tissue after reperfusion based on anonymized clinical, imaging,
and thrombus histopathological data from the Multicenter
Randomized Clinical Trial of Endovascular Treatment for Acute
Ischemic Stroke in the Netherlands (MR CLEAN) trial, the MR
CLEAN Registry and the HERMES collaboration (1, 2, 24).
We will validate these ISMs using laboratory experiments and
available anonymized clinical data. We aim to apply these ISMs
to virtual patient populations with AIS with the goal to generate
an IST platform, followed by validation and application of the
IST platform.
Patient Population
Anonymized baseline (clinical and imaging) data, treatment
characteristics and outcome (clinical and imaging) data from
patients included in the MR CLEAN trial (2). MR CLEAN
Registry (24) and the HERMES collaboration (1), totaling
over 4,500 patients will be used to develop, execute, and
validate the ISMs and ISTs. Anonymized data from on-
going RCTs in AIS patients within the Collaboration for New
Treatments of Acute Ischemic Stroke (CONTRAST) consortium
(www.contrast-consortium.nl) comprising of ∼2,500 patients
will also be included in this project. The anonymized data from
the HERMES (1) and CONTRAST collaboration will be used to
validate the ISTs.
Design
The IST consists of four main software modules (Figure 1). The
first module generates virtual populations of AIS patients; the
second simulates treatment and brain tissue injury; the third
estimates outcome for each individual virtual AIS patient and the
final module assembles all results and reports the outcome.
Module I: Population Model to Generate Virtual
Populations of AIS Patients
We aim to generate virtual populations of AIS patients,
that are defined using probability density function(s) over all
relevant patient specific characteristics, including correlations,
and interactions between them, as required by the computational
models in Module II and statistical models in Module III. To
mitigate the effects of selection bias, the virtual population model
is based on anonymized data from the MR CLEAN Registry: a
nationwide registry that includes all patients with an AIS due to
a large vessel occlusion in the anterior circulation that received
endovascular treatment; and not on data from a trial population
with very strict inclusion and exclusion criteria.
The virtual population model is developed using 15
characteristics including, clinical (age, sex, systolic blood
pressure at admission, pre-interventional modified Rankin Scale,
NIH Stroke Scale, comorbidities like previous stroke, diabetes
mellitus, atrial fibrillation), workflow based (time from onset to
emergency room, time from emergency room to groin puncture),
imaging (occlusion location, collateral score, ASPECTS), and clot
characteristics (presence of a hyperdense artery sign on baseline
NCCT, percentage of fibrin/RBC based on histological analysis).
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FIGURE 1 | Schematic overview of the INSIST approach to implement an IST for AIS.
These characteristics have been selected based on prior clinical
knowledge of clinicians within the consortium, previously
validated stroke prediction platform (25) and requirements of the
ISMs of treatment. By mainly deriving the characteristics from
a previously validated prediction model and using a relatively
large dataset approximating over 4,500 patients, we limit the
effects of over-fitting. To improve the accuracy of estimating
the correlations of population characteristics (for example—
percentage of fibrin/RBC) that are only available for a subset of
the dataset, correlations of such characteristics are only estimated
with characteristics that are available for the entire population
and that they are most associated with to improve accuracy (for
example—occlusion location).
Furthermore, the virtual populations are developed using the
vine copula model. Compared to state of the art techniques like
conditional regression and imputation methods, the vine copula
model has several advantages including capturing interactions
between the characteristics describing the population as lower
levels of dependence structures (26–28).
Vessel geometry, clot atlas and ischemic core atlas
Validated (semi-) automated quantitative methods to extract
information from radiological images like collateral capacity
(29), early ischemic changes (30), thrombus characteristics
(10, 31), infarct (32), and hemorrhage (33) characteristics are
available to determine radiological characteristics of follow
up. We are creating a library of vessel geometries based
on the intracranial arteries segmented from baseline imaging
data. Segmentation of intracranial arteries is performed using
artificial intelligence based techniques. We are also identifying
and categorizing different phenotypes of aortic arch-types and
intracranial vascular anatomies. In addition, we are performing
analysis ofmultiple thrombus features [e.g., size (length, volume),
location, perviousness, etc.] obtained from baseline imaging data
(10). We are extending previous methods to create ischemic core
atlases to predict the size and location of the final infarct based
on the thrombus location, composition, and collateral score.
Furthermore, we are creating probability maps of infarcts that
indicate the chance of having an infarct in a specific region based
on prior clinical, imaging, and treatment information (34).
Relationship between clinical, imaging, and histological
characteristics of thrombi
We analyze the clots retrieved after EVT procedure for
patients within the MR CLEAN Registry (24) using routine
macroscopy, histology with various stainings and with immuno-
histochemistry using confocal microscopy and (immuno-)
scanning electron microscopy. We quantify the thrombus
components and their contribution to the thrombus. We also
perform electron microscopy of the stents to study the stent-
thrombus interaction and its dependence on clot composition
(35, 36). With these measurements we will create a clot database
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and use it to generate a clot population model after incorporating
clinical characteristics (such as age, sex, stroke etiology, and
prior IV-alteplase), procedural characteristics (time from onset
to alteplase, time from alteplase to intra-arterial thrombectomy),
and interventional characteristics (stent-retriever, aspiration).
Generation and validation of virtual patients
and populations
Based on the population models described in the previous
sections, virtual patients are created by randomly sampling
from the distributions, while accounting for inclusion criteria
that may be required in a specific IST. A virtual patient is
defined as a combination of characteristics including clinical,
anatomical data, and clot specifics, and is used as input to the
computational models in Module II. We will combine a large
number of individual virtual stroke patients to generate virtual
cohorts. Specific virtual cohorts can be generated by setting
characteristics, such as age, sex, and baseline NIH Stroke Scale,
like setting in- and exclusion criteria in RCTs (26–28).
Module II: Simulate Treatment and Brain Tissue Injury
We intend to simulate brain perfusion and growth of an ischemic
lesion after AIS (pre- and post-treatment) for every virtual patient
generated in Module I. Thus, the output of this Module will
include an estimate of the lesion characteristics like location and
volume, and status of recanalization and reperfusion for every
virtual AIS patient.
The onset of AIS serves as a starting point of the simulations
in this Module. Clot characteristics like location and size and
time from onset to treatment are derived from the population
model. We then simulate the flow adjustment in response to
the occlusion of artery in 1-D models for the large blood
vessels that are coupled to simulations of brain tissue perfusion.
Treatment, modeled as the (partial) opening of the arterial
segment, mimics the details of thrombolysis, and thrombectomy.
We also incorporate the possible spray of micro-emboli in the
treatment models. The redistribution of the blood flow in the
brain is then fed to a 3-D homogenized tissue level perfusion
model that describes the (lack of) perfusion of the brain over
time, which is the input for the homogenized 3-D brain level
stroke model. Figure 2 shows a schematic overview of this
multiscale model of AIS and its treatment.
In-silico models for simulation of thrombosis
and thrombolysis
Within INSIST, we develop numerical mathematical models,
based on bio-physical principles, in order to explain and predict
the processes of thrombosis and thrombolysis relevant to stroke
events. The main goal is to understand the formation of
the clot, as well as its 3D structure (porosity, composition,
inhomogeneity) and what makes some patients resistant to
thrombolysis. The proposed models include the most relevant
blood factors, nature of treatment, vessel geometry, and flow
properties to simulate various patient specific scenarios. The
mathematical models include two levels of description: first a 1D
macroscopic approach, based on a system of partial differential
equations, with validated bio-physical reaction constants, but
limited to simple geometries and second, a 3Dmesoscopic model
able to consider arbitrary flow situations and an explicit structure
of the clot. The second model implements the thrombosis
and thrombolysis processes as dynamics of idealized particles,
transported by a Lattice Boltzmann fluid. These two models
typically return lysis time and lysed volume for different
situations (depending on flow condition, clot structure, blood
composition, etc.). They are being validated with in-vitro
experiments, performed by INSIST partners.
In-silico models of mechanical thrombectomy
We are developing ISMs of the stent-retriever, stent placement
and stent-thrombus interaction that are driven by in vitro and ex-
vivo experiments with and without thrombolysis treatment. The
developed models generate measures of recanalization and clot
fragmentation. We are also incorporating the biomechanics of
thrombus-vessel adhesion into these models. By simulating the
interaction between the stent-retrievers and the vessel wall, we
will be able to assess the potential for tissue damage associated
with the forces applied by the retriever during deployment and
shear stress induced during the retrieving operation. These ISMs
are be based on the established techniques of finite element
modeling of stent-retrievers (37, 38).
Blood flow, perfusion, and microcirculation modeling
With the vessel models, we can generate virtual patient specific
1D blood flow models for the large conductance vessels in the
brain (39–43). We are extending these models toward the smaller
pial vessels, covering the leptomeningeal collateral network (44,
45). Since there are hundreds of millions of arterial and arteriolar
segments in the human brain, modeling individual segments
below a certain branching level is neither feasible nor required.
We, therefore, use homogenized models for the distribution of
number and size of penetrating vessels over the cortex and for
the downstream microvascular beds. Such homogenized models
are based on porous media physics and include a description of
perfusion in terms of Darcy’s law, considering the anisotropic
nature of the vascular bed (46, 47). Essentially all arteries, but
notably the arterioles have significant resistance for perfusion.
Control of arteriolar diameter by smooth muscle contractile
activity is a core process in autoregulation of brain perfusion, and
this process is strongly affected in AIS and during reperfusion
(48). The models will be validated in individual subjects through
angiographic imaging and perfusion mapping and will be
used to assess the robustness of the circulatory pathways to
alterations in supply or to changes in individual vessels (for
example micro-emboli).
In-silico ischemia models
We will couple models of the cell response to hypoxia with
models of hypo-perfusion injury (49–51). Using homogenization
techniques, the models of the microvasculature can be scaled
across multiple length scales, which will result in a full advection-
convection-diffusion equation, to be performed in the context
of both a response to a large clot in a large supply vessel
and to micro-emboli in multiple vessels. The resulting 3D
model of hypo-perfusion injury will consider the whole cycle of
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FIGURE 2 | Schematic overview of the multiscale model that simulates AIS and its treatment.
hypo-perfusion, tissue damage and reperfusion within a single,
dynamically varying, model for the first time. We will combine
models of cerebral blood flow with those of cerebral metabolism,
using multi-scale techniques to develop models that incorporate
the behavior at both the cellular level and the tissue level.
Module III: Outcome Estimation at Patient Level
Characteristics of the final lesion like location and volume
are known to be important indicators of patient outcome (15,
19). In this Module, a statistical model that correlates the
output of Module II in combination with clinical parameters to
patient outcome is developed. Specifically, we will statistically
estimate early neurologic deficit as a primary outcome measure.
Adverse events, including intracranial hemorrhages, will not be
modeled by the in-silicomodels, but will be statistically estimated.
Modified Rankin Scale after 90 days is then predicted based
on the estimated treatment success, early neurological deficit
and adverse events. By executing Modules II and III for each
virtual stroke patient in the virtual population, we generate an
output dataset that includes the recanalization and reperfusion
status, infarct characteristics and functional outcome for each
virtual patient.
Module IV: Report Outcome at Population Level
In this Module, we will translate and aggregate the results
obtained from the previous Module for each individual virtual
stroke patients and report results on the population level, such
that comparison with real RCTs becomes possible. The Modules
mentioned above are implemented as standardized and stand-
alone software packages. The overall IST is then implemented
as a standard workflow, for which we will be using the Kepler
system (see https://kepler-project.org) to enable easy plug-and-
play features.
Validation
Evaluating the credibility of an IST requires careful and complete
validation of all separate components that constitute the trial, and
the validation of the complete integrated IST.We will validate the
integrated ISMs that are applied to the virtual populations of AIS
patients using the anonymized data from the associated trials.
We will simulate the trial population and treatment as performed
in each of the 7 RCTs, with the IST platform developed in this
project using anonymized data from only 6 RCTs (1, 2). We
will also perform blinded comparison with the recently started
CONTRAST trials (www.contrast-consortium.nl). Specifically,
we will compare the distributions and correlations of this
virtual cohort to the baseline characteristics of the population
enrolled in simulated trial and provide measures of model
performance such as calibration and discrimination. Our
validation will follow the formal Verification, Validation, and
Uncertainty Quantification (VVUQ) procedures as outlined by
the ASME V&V40 subcommittee on verification and validation
in computational modeling of medical devices, which was
published in early 2017 (52) and which FDA has adopted for
computational models used for clinical decision support for
introduction of new devices.
ANTICIPATED RESULTS
We believe that accurate tailoring of the above-mentioned
Modules will help to build a platform that can be used to execute
and conduct ISTs. We have identified three key hypotheses that
would be of interest to healthcare professionals, modelers, and
pharmaceutical and device industry to explore and refine using
the validated IST platform:
i Alternative configurations of stent-retrievers, local distal
access catheters, aspiration devices, and balloon guide
aspiration devices that can reduce thrombus fragmentation
will result in improved treatment outcome.
ii Drugs that reduce active Thrombin-Activatable Fibrinolysis
Inhibitor (TAFIa) can improve recanalization by tissue
plasminogen activator and provide better microvascular
reperfusion after thrombectomy.
iii Patients with AIS due to large vessel occlusion benefit from
an early start of thrombectomy, before the administration
of thrombolysis.
We will focus on the optimization of medication administration
(pharma industry), use of medical devices (device industry) to
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improve procedural and peri-procedural aspects of therapy and
improved patient stratification for personalized thrombolytic
and/or thrombectomy treatment (clinicians).
DISCUSSION
In this white paper, we describe a methodology that should
enable an initial assessment of the added value of ISTs and
provide insights into the best practices in setting up such ISTs.
We believe that the results of the in-silico platform may provide
information at a population level given the cohort characteristics,
and not on the individual patient level for clinical decision
making. Nevertheless, the results of the in-silico platform can
provide insight on the efficacy of new treatments. The ISTs can
be performed for different virtual populations. In all cases, one of
our end goals will be to optimize the design of a real-life clinical
trial. Hence, we will develop and implement protocols that will
enable us to run all ISTs multiple times sweeping over parameters
that need to be optimized in a(n) (computationally) efficient way.
By the end of the project we will have obtained a much deeper
understanding of the pathophysiology of AIS and reasons for
failure of current treatments, have delivered and assessed ISMs
that explain treatment efficacy. Moreover, the accuracy of ISTs
will be assessed by comparing their results with the findings from
running and recently completed clinical trials.
We envision that an integrated approach of multiple ISMs in
combination with accurate virtual populations of stroke patients
will provide valuable insights for the design of relavant trials and
thus, contribute to improved biomedical products and treatment
success. Nevertheless, ISTs cannot replace clinical trials as ISMs
and ISTs are based on data generated from the controlled settings
of clinical trials. However, as advertised now by the FDA and
EMA, ISTs have value to improve clinical trial design and enhance
the level of evidence so that less clinical trials are required before
approval from the regulatory bodies.
There are various foreseeable limitations to this study. We
must acknowledge that modeling brain tissue infarction, and the
complex chain of events that all play a role in brain perfusion
andmetabolism is very challenging.We still lack basic knowledge
of the underlying physiology, as well as sufficiently detailed
experimental data that would allow detailed modeling of these
processes. However, by reporting outcomes at a population
level and by combining a statistically driven component to the
modeling chain (as in Module III), the outcome of the IST can
become robust to modeling errors of the individual components
of an IST. Detailed validation studies will shed light on this for
AIS ISTs and for ISTs in general.
CONCLUSION
ISTs have the potential to lead to a more effective human clinical
trial design, reduce animal testing, lower development costs, and
shorten time to market for new medical products. ISTs also allow
improved prediction of human risk for new biomedical products.
In addition, there is the potential to reuse the developed ISMs
for drug repositioning. Through this project, we aim to show the
credibility of ISTs and work toward the regulatory acceptance
of in-silico computational modeling for decision-making and
pre-market submissions.
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